Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific, Agios Pharmaceuticals to Codevelop Glioma Companion Diagnostic

NEW YORK – Thermo Fisher Scientific said on Tuesday that it has expanded its strategic partnership with Agios Pharmaceuticals to codevelop a companion diagnostic test to identify low-grade glioma patients with IDH1 and IDH2 mutations who may be eligible for Agios' investigational inhibitor vorasidenib.

Under the agreement, the partners will develop a companion diagnostic for vorasidenib, currently under evaluation in the Phase 3 INDIGO study, using Thermo Fisher's Oncomine Precision Assay, a next-generation sequencing panel on the Genexsus system that covers more than 50 genomic targets. Thermo will retain the rights to commercialize the test globally and will take the lead in seeking clearance from appropriate regulatory agencies.

The new deal follows a similar 2017 agreement between the companies to develop and commercialize a companion diagnostic to identify patients with IDH1-mutant cholangiocarcinoma who may be eligible for ivosidenib (marketed by Agios as Tibsovo). Data from the resulting Phase 3 ClarIDHy clinical study were presented at the last year's European Society for Medical Oncology Congress.

Financial terms of the expanded agreement were not disclosed.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.